Biosimilars Could Cut Spending for Biologic Therapy in the US
Increased market growth of biosimilars that are similar to brand-name biologic agents has the potential to reduce spending on prescription drugs
Urologic Disorders
Donepezil Tied to Risk for Overactive Bladder
Risk for overactive bladder varies across individual cholinesterase inhibitor drugs
Tebipenem HBr Gets Priority Review for Oral Treatment of Complicated UTI
The application includes data from the phase 3 ADAPT-PO trial, which evaluated the efficacy and safety of tebipenem HBr in 868 adults with cUTI or acute pyelonephritis.
MPR Weekly Dose Podcast Episode 102
Contraindication added to Janssen COVID-19 vaccine; Pfizer announce final results for their COVID-19 oral antiviral; A new treatment for benign prostatic hyperplasia; REMS change for CAR T-cell therapy, and Rinvoq gains approval for active psoriatic arthritis.
E-Cigarettes May Up the Risk for Erectile Dysfunction
Findings for men between 20 and 65 years of age with no prior history of cardiovascular disease
Entadfi Approved for Benign Prostatic Hyperplasia
Entadfi is a fixed-dose combination of finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor.
FDA Approves Urethral Stricture Treatment Optilume
The Optilume device includes a balloon coated with paclitaxel.
Outcomes Worse for Hospitalized Patients With Incontinence
Outcomes even worse for hospitalized patients with incontinence who require treatment of incontinence-associated dermatitis
FDA Panel Votes on Bardoxolone for CKD Caused by Alport Syndrome
The Committee voted “no on the question of whether the provided evidence demonstrated that bardoxolone is effective in slowing the progression of CKD in patients with Alport syndrome and that its benefits outweigh its risks.”
Belimumab Promising in Combination Therapy for Refractory Lupus
Lower serum IgG anti-dsDNA antibody levels seen at 52 weeks with belimumab rather than placebo given after rituximab
